| Abstrakt: |
Every year about 800,000 complete suicide events occur. The identification of biologic markers to identify subjects at risk would be helpful in targeting specific support treatments. A narrative review defines the meta-analytic level of current evidence about the biologic markers of suicide behavior (SB). The meta-analytic evidence gathered so far indicates that the hypothesis-driven research largely failed to identify the biologic markers of suicide. The most consistent and replicated result was reported for: 1) 5-HTR2A T102C, associated with SB in patients with schizophrenia (OR = 1.73 (1.11–2.69)) and 2) BDNF Val66Met (rs6265), with the Met-Val + Val–Val carriers found to be at risk for suicide in the Caucasian population (OR: 1.96 (1.58–2.43)), while Val–Val vs. Val–Met + Met carriers found to be at risk for suicide in the Asian populations (OR: 1.36 (1.04–1.78)). GWAS-based meta-analyses indicate some positive replicated findings regarding the DRD2, Neuroligin gene, estrogen-related genes, and genes involved in gene expression. Most consistent results were obtained when analyzing sub-samples of patients. Some promising results come from the implementation of the polygenic risk score. There is no current consensus about an implementable biomarker for SB. [ABSTRACT FROM AUTHOR] |
